Ambrohexal, pills 30mg, 20pcs

Composition

One tablet contains: Active ingredient: ambroxol hydrochloride-30.0 mg; excipients: lactose monohydrate – 102,0 mg;calcium hydrogen phosphate dihydrate – 50.0 mg;corn starch – 10,0 mg;sodium carboximetilkrahmal – 4.0 mg;magnesium stearate 2.0 mg;silicon dioxide colloidal – 2,0 mg.

Pharmacological effects

for the Treatment of medicinal drug that has mucolytic, expectorant and secretolytic effect, and the active Active ingredient of the drug is Ambroxol.

The mechanism of action of this drug is associated with a decrease in sputum viscosity as a result of depolymerization of sputum mucopolysaccharides, which consists in breaking disulfide bonds in molecules, increasing the release of active hydrolyzing enzymes from Clark cells.

Ambrogexal also increases the activity of the cilia of the bronchial epithelium, and normalizes the ratio of all sputum components and, therefore, stimulates its mucociliary transport. This facilitates expectoration of sputum from the respiratory tract, and also stimulates the secretion and blocking of surfactant breakdown.

Ambrohexal is rapidly absorbed from the gastrointestinal tract, having a high absorption capacity, and its optimal plasma concentration is reached within two hours after taking the drug: tablets, syrup, capsules with prolonged action and a solution for inhalation.

The effect of the drug occurs when taken in the form of syrup or tablets – after 30 minutes and depends on the rate of absorption of the drug in the stomach and intestines. The metabolism of this drug occurs in the liver, where it is converted to dobramantranilic acid and glucuronic conjugates, and is excreted from the body by the kidneys.

Indications

Acute, bronchitis with difficulty passing sputum, pneumoconiosis, bronchial asthma, tuberculosis and cystic fibrosis of the lungs, bronchiectasis, acute pneumonia, pleurisy, emphysema of the lungs, acute, prolonged and chronic sinusitis, chronic rhinitis.

Use during pregnancy and lactation

The drug is contraindicated for use during the first trimester of pregnancy. Application of Ambrogexal® during pregnancy (II-III trimester) is possible only if the intended benefit to the mother exceeds the potential risk to the fetus or infant. Ambroxol penetrates the placental barrier. Animal studies have shown that the drug has no effect on embryophetal development, childbirth and postnatal development. Ambroxol is excreted in small amounts in breast milk, so when taking Ambrohexal®, it is necessary to decide whether to stop breastfeeding.

Contraindications

• Hypersensitivity to the components of the drug;
• pregnancy (I trimester).
• peptic ulcer of the stomach and duodenum

With caution:  patients with renal and hepatic insufficiency.

Side effects

From the digestive system:  nausea, vomiting, gastralgia, diarrhea, constipation, dry mouth.

Allergic reactions:  skin rash, urticaria, angioedema, bronchospasm attack, fever with chills; anaphylactic shock; weakness, headache, rhinorrhea, increased salivation, dry airways, urination disorders (dysuria).

Interaction

Combined use with antitussive drugs leads to difficulty in sputum discharge against the background of suppression of the cough reflex. Increases the penetration of amoxicillin, cefuroxime, erythromycin and doxycycline into the bronchial secretion.

How to take, course of use and dosage

Inside, after eating with a sufficient amount of liquid.

Adults and children over 12 years of age — 1 tablet (30 mg ambroxol) 3 times a day for the first 2-3 days, then the dose of the drug should be reduced to 1 tablet. 2 times a day.

Children aged 6-12 years — 1/2 tablet (15 mg ambroxol) 2-3 times a day.

The duration of therapy depends on the severity of the disease and is determined by the attending physician. Do not take Ambrogexal® for more than 4-5 days without a doctor’s recommendation.

The mucolytic effect is enhanced with additional fluid intake. Therefore, it is necessary to consume a sufficient amount of fluids (juices, tea, water) during treatment.

Overdose

Symptoms:  nausea, vomiting, gastralgia. There are reports of short-term anxiety and diarrhea. With a severe overdose, a drop in blood pressure is possible.

Treatment:  induction of vomiting, gastric lavage in the first 1-2 hours after taking the drug, use of fat-containing products.

Special instructions

Ambroxol should be used with caution in patients with a weakened cough reflex or impaired mucociliary transport due to the possibility of sputum accumulation.

Patients taking ambroxol should not be recommended to perform breathing exercises; in seriously ill patients, aspiration of liquefied sputum should be performed.

In patients with asthma, ambroxol may worsen coughing.

Do not take ambroxol immediately before bedtime.

Ambroxol should not be taken concomitantly with antitussive medications that may inhibit the cough reflex, such as codeine, as this may make it difficult to remove diluted sputum from the bronchial tree.

Instructions for patients with diabetes mellitus:  1 tablet contains less than 0.01 XE.

Form of production

Tablets

Storage conditions

The drug should be stored at a temperature not exceeding 25°C.

Shelf life

2 years

Active ingredient

Ambroxol

Dosage form

Tablets

Description

Nursing mothers as prescribed by a doctor, Children over 6 years of age, For adults, Pregnant women in the second and third trimester as prescribed by a doctor

Indications

Chronic obstructive pulmonary disease, Cold, Bronchitis, Flu, Otitis media, Cough, Sinusitis, Bronchial asthma, pneumonia